FINWIRES · TerminalLIVE
FINWIRES

BMO Cites "More Grim News" For Ontario Homeowners With "Massive Overhang of Unsold New Condos"

-- The March existing home sales report brought "more grim news" for Ontario homeowners, particularly in the Greater Toronto-Hamilton Area, where the price correction has now entered a fifth year, said Bank of Montreal (BMO) in an overnight note.

One reason is the "massive overhang" of unsold new condos, which stood 40% above the long-run average as of Q4 2025, noted the bank.

"With interest rates holding steady, the only quick way to clear this glut is through price cuts and possibly large ones, given competition from a much cheaper resale market (that's now largely within reach of the median income earner)", said BMO.

BMO noted the average new condo price of $1,344 per square foot in Q4 2025 was 78%, or $587, above the average resale price of $757. This gap has "ballooned" out from just 31%, or $144, a decade ago.

The recently introduced HST rebate of up to 13% on new condos, or about $175 per square foot, won't normalize the gap but will at least help builders work down the oversupply, added BMO.

Related Articles

Asia

Beijing Enlight Media Q1 Profit Falls 99%; Shares Down 8%

Beijing Enlight Media Co (SHE:300251) posted first-quarter attributable net profit of 23.3 million yuan, down 99% from 2.02 billion yuan the previous year.Earnings per share went down to 0.01 yuan from 0.69 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue fell 94% year over year to 190.6 million yuan from 2.97 billion yuan.Shares of the media company were down 8% in recent trade.

$SHE:300251
Asia

Enlight Media 2025 Profit Jumps 473%; Shares Fall 7%

Beijing Enlight Media (SHE:300251) posted 2025 attributable net profit of 1.67 billion yuan, up 473% from 292.0 million yuan the previous year.Earnings per share went up to 0.57 yuan from 0.10 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue jumped 155% year over year to 4.04 billion yuan from 1.59 billion yuan.Shares of the media company were down 7% in recent trade.

$SHE:300251
Asia

CR Double-Crane Pharma Gets Nod to Name Unit as Marketer of Endometriosis Drug

China Resources Double-Crane Pharmaceutical (SHA:600062) received approval from the National Medical Products Administration to change the marketing authorization holder of dienogest tablets, according to a Shanghai bourse filing on Wednesday.Under the approved supplementary application, the pharmaceutical company's subsidiary, CR Zizhu Pharmaceutical, becomes the marketing authorization holder, as well as the manufacturer of the endometriosis drug.

$SHA:600062